Open an account

Sunshine Biopharma

SBFM · NASDAQ

$0.22−$0.0218 (−9.02%)TodayMarket closed ·
Prev close $0.2418

About SBFM

Sunshine Biopharma, Inc. is a pharmaceutical company, which engages in the research, development, and commercialization of oncology and antiviral drugs. The company is headquartered in Fort Lauderdale, Florida and currently employs 50 full-time employees. The company went IPO on 2008-08-15. The firm has approximately 70 generic prescription drugs on the market in Canada. In addition, the Company is conducting a proprietary drug development program which is comprised of K1.1 mRNA, an mRNA-Lipid Nanoparticle targeted for liver cancer, and PLpro protease inhibitor, a small molecule for the treatment of SARS Coronavirus infections. The firm operates through two segments: Prescription Generic Pharmaceuticals (Generic Pharmaceuticals) and Nonprescription Over-The-Counter Products (OTC Products). The firm operates two wholly owned subsidiaries: Nora Pharma Inc., which has a portfolio of pharmaceutical products consisting of various prescription drugs on the market in Canada, and Sunshine Biopharma Canada Inc., which develops and sells nonprescription over-the-counter (OTC) products.

Employees
50
Headquarters
FORT LAUDERDALE, Florida
Listed
Aug 15, 2008
Sector
Health Care
Industry
Biotechnology
Website
sunshinebiopharma.com

SBFM key statistics

Market cap
948.27K
Price-earnings ratio
0.00
Dividend yield
—
Average volume
16.16M
Volume
493.27K
Open price
$0.234
High today
$0.2438
Low today
$0.2138
52 Week high
$23.20
52 Week low
$0.1855

Sunshine Biopharma (SBFM) at a glance

As of Oct 20, 2026, Sunshine Biopharma (SBFM) shares are priced at $0.22, giving the company a market cap of 948.27K and a price-to-earnings ratio of 0.00.

Today the stock has traded between $0.2138 and $0.2438. The current price is 2.9% above the day's low and 9.8% below its high.

Volume so far is 493.27K shares, below the average of 16.16M shares a day.

Over the past year Sunshine Biopharma has ranged from $0.1855 to $23.20, and now sits 0% of the way up that range.

Sunshine Biopharma met or beat analyst EPS estimates in 0 of the last 8 quarters. In Q1 FY26 it reported -$0.25 per share against an estimate of $0.00.

SBFM earnings

Earnings per share, reported against the analyst estimate

Didn’t beat the estimate in any of the last 8 quarters.

  1. Q1 FY24: reported -$400.00 per share against an estimate of -$212.16
  2. Q2 FY24: reported -$99.40 per share against an estimate of -$75.48
  3. Q3 FY24: reported -$9.40 per share against an estimate of $91.80
  4. Q4 FY24: reported -$10.00 per share against an estimate of $1.12
  5. Q2 FY25: reported -$3.90 per share against an estimate of -$1.12
  6. Q3 FY25: reported -$1.90 per share against an estimate of -$1.33
  7. Q4 FY25: reported -$5.40 per share against an estimate of -$2.75
  8. Q1 FY26: reported -$0.25 per share against an estimate of $0.00

SBFM news

  • Avi Kapoor

    Crude Oil Gains 5%; PepsiCo Posts Upbeat Q3 Earnings

  • Avi Kapoor

    Dow Falls Over 100 Points; US Initial Jobless Claims Decline

  • Avi Kapoor

    US Stocks Mixed; Nasdaq Gains Over 50 Points

  • Vandana Singh

    EXCLUSIVE: Sunshine Biopharma Advances 'Differentiated Antiviral Candidate' to IND-Enabling Studies

  • Press releaseGlobe Newswire

    A Multibillion-Dollar mRNA Cancer Market Is Taking Shape Targeting Lung Cancer’s Biggest Opportunity

  • Vandana Singh

    EXCLUSIVE: Sunshine Biopharma Advances Vaccine Strategy for Lung Cancer

  • Vandana Singh

    EXCLUSIVE: Sunshine Biopharma Secures Canadian Approval for Generic Hypertension Drug

  • Vandana Singh

    EXCLUSIVE: Sunshine Biopharma Targets Canadian Market with New Women's Health Drug Approval

Similar companies

Companies in the same industry as Sunshine Biopharma

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.